Search This Blog

Saturday, June 4, 2016

Lilly Announces Results from MONARCH 1 Trial of Abemaciclib Monotherapy (NYSE:LLY)

Phase 2 Data Confirms Single-Agent Activity of Abemaciclib Dosed on a Continuous Schedule in HR+, HER2- Metastatic Breast Cancer Patients



Lilly Announces Results from MONARCH 1 Trial of Abemaciclib Monotherapy (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.